FDA-cleared profile

EFAI ERSUITE CT APPENDICITIS ASSESSMENT SYSTEM (APPEN-CT-100)

Ever Fortune.Ai, Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Triage notification of suspected appendicitis on contrast-enhanced abdominal CT

Clinical role
Triage or notification support
Images and patients
CT/CTA · Abdomen
Key limitation
Keep in mind: Not a diagnostic device and does not alter the original image. Clinicians must review full images and all patient information under standard care.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Triage notification of suspected appendicitis on contrast-enhanced abdominal CT
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Abdomen Input: Contrast-enhanced abdominal CT DICOM images
  • Who uses it?Intended users: Hospital networks and trained clinicians
  • What does the software produce?Output: Case-level text/JSON notification to PACS/RIS/workstation; no DICOM viewer, image overlay, location marking, worklist reprioritization or removal.
  • What is its most important limitation?Key limitation: Not a diagnostic device and does not alter the original image. Clinicians must review full images and all patient information under standard care.

Clinical takeaway. Clinical role: Triage notification of suspected appendicitis on contrast-enhanced abdominal CT

Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded multisite study of 300 consecutive US CTs, 139 positive and 161 negative, with three board-certified radiologists and majority reference. Mean processing time was 3.37 minutes in the study, not a service-level commitment.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Triage notification of suspected appendicitis on contrast-enhanced abdominal CT
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Triage or notification support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Contrast-enhanced abdominal CT DICOM images
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Case-level text/JSON notification to PACS/RIS/workstation; no DICOM viewer, image overlay, location marking, worklist reprioritization or removal.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Hospital networks and trained clinicians
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Not a diagnostic device and does not alter the original image. Clinicians must review full images and all patient information under standard care.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Retrospective blinded multisite study of 300 consecutive US CTs, 139 positive and 161 negative, with three board-certified radiologists and majority reference. Mean processing time was 3.37 minutes in the study, not a service-level commitment.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective blinded multisite study of 300 consecutive US CTs, 139 positive and 161 negative, with three board-certified radiologists and majority reference. Mean processing time was 3.37 minutes in the study, not a service-level commitment.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
92.8% (95% CI 87.3%-96.0%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported specificity
93.2% (95% CI 88.2%-96.1%)
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Sensitivity

92.8 %

  • EndpointSuspected appendicitis case triage
  • Population300 consecutive US contrast-enhanced abdominal CTs
  • Tested versionAPPEN-CT-100 in K253163

Specificity

93.2 %

  • EndpointSuspected appendicitis case triage
  • Population300 consecutive US contrast-enhanced abdominal CTs
  • Tested versionAPPEN-CT-100 in K253163

K253163 appendicitis triage standalone study

  • DesignRetrospective blinded multisite standalone performance study
  • Population300 consecutive US CTs; 139 appendicitis-positive, 161 negative
  • Scopeexact submission
  • Tested versionAPPEN-CT-100
  • Samplen=300
  • IndependenceIndependence not established

K253163

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast-enhanced abdominal CT DICOM images

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · EFAI ERSUITE CT Appendicitis Assessment System: K253163 decision and 510(k) summary

  2. Routing

    Source context, not route validation: Passive JSON notification into PACS/RIS workstation workflow

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · EFAI ERSUITE CT Appendicitis Assessment System: K253163 decision and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Hosting and local network topology were not established.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: Case-level text/JSON notification to PACS/RIS/workstation; no DICOM viewer, image overlay, location marking, worklist reprioritization or removal.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · EFAI ERSUITE CT Appendicitis Assessment System: K253163 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Case-level text/JSON notification to PACS/RIS/workstation; no DICOM viewer, image overlay, location marking, worklist reprioritization or removal.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · EFAI ERSUITE CT Appendicitis Assessment System: K253163 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Passive JSON notification into PACS/RIS workstation workflow
  • Exact FDA submission
  • Checked 2026-09-05
Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Vendor emergency-imaging context

Vendor positions CT-based AI assistance for emergency and radiology workflows.

product family · checked 2026-09-06

Page does not establish APPEN-CT-100-specific interfaces or performance.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253163
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Abdomen
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-04-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed and clinical-trial arrays are empty and were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-06 - Exact FDA submission

    No exact product price/procurement record reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Ever Fortune.AI EFAI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Hosting and local network topology were not established.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Site triage escalation and notification training are unestablished.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Site audit of alert delivery and missed/false alerts requires confirmation.

9 sources - 3 history items

Source ledger

  1. K253163 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. EFAI ERSUITE CT APPENDICITIS ASSESSMENT SYSTEM (APPEN-CT-100) model card (K253163)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. EFAI ERSUITE CT Appendicitis Assessment System: K253163 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  8. Ever Fortune AI medical imaging solutions

    Ever Fortune.AI - Accessed 2026-09-06

    Scope: implementation

  9. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K253163 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253265

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult abdominal CT triage for suspected intra-abdominal free gas.

Modality
CT/CTA
Anatomy
Abdomen
Decision
2025-11-06
FDA-cleared K193298

BriefCase

Aidoc Medical, Ltd.

BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of abdominal CT images. The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive findings of Intra-abdominal free gas (IFG) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.

Modality
CT/CTA
Anatomy
Abdomen
Decision
2020-06-19
FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history